JP5624276B2
(ja)
|
2006-03-31 |
2014-11-12 |
中外製薬株式会社 |
抗体の血中動態を制御する方法
|
SI2173379T1
(sl)
|
2007-07-02 |
2015-12-31 |
Oncomed Pharmaceuticals, Inc. |
Sestavki in postopki za zdravljenje in diagnosticiranje raka
|
EP3689912A1
(en)
|
2007-09-26 |
2020-08-05 |
Chugai Seiyaku Kabushiki Kaisha |
Method of modifying isoelectric point of antibody via amino acid substitution in cdr
|
TW201447062A
(zh)
|
2008-04-11 |
2014-12-16 |
Chugai Pharmaceutical Co Ltd |
重複結合複數個抗原的抗原結合分子
|
ES2788869T3
(es)
|
2009-09-03 |
2020-10-23 |
Merck Sharp & Dohme |
Anticuerpos anti-GITR
|
EP2647706B1
(en)
|
2010-11-30 |
2023-05-17 |
Chugai Seiyaku Kabushiki Kaisha |
Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly
|
JP6400470B2
(ja)
|
2011-05-16 |
2018-10-03 |
ジェネロン(シャンハイ)コーポレイション リミテッド |
多重特異性Fab融合タンパク質および使用法
|
CN106167526A
(zh)
|
2011-07-15 |
2016-11-30 |
昂考梅德药品有限公司 |
Rspo结合剂和其应用
|
WO2013039954A1
(en)
*
|
2011-09-14 |
2013-03-21 |
Sanofi |
Anti-gitr antibodies
|
KR101566539B1
(ko)
|
2012-06-08 |
2015-11-05 |
국립암센터 |
신규한 Th2 세포 전환용 에피토프 및 이의 용도
|
EP2872175A4
(en)
|
2012-07-13 |
2016-04-20 |
Oncomed Pharm Inc |
RSPO3-BONDING SUBSTANCES AND USES THEREOF
|
EP2889376A4
(en)
|
2012-08-24 |
2016-11-02 |
Chugai Pharmaceutical Co Ltd |
ANTIBODIES Fc SPECIFIC TO FCTRII OF MOUSE
|
NZ705370A
(en)
|
2012-08-24 |
2018-06-29 |
Chugai Pharmaceutical Co Ltd |
Fcγriib-specific fc region variant
|
US10548957B2
(en)
|
2012-09-28 |
2020-02-04 |
Dana-Farber Cancer Institute, Inc. |
Targeted expansion of Qa-1-peptide-specific regulatory CD8 T cells to ameliorate arthritis
|
HRP20190574T1
(hr)
|
2012-12-03 |
2019-05-17 |
Bristol-Myers Squibb Company |
Poboljšanje anti-kancerogene aktivnosti imunomodulatornih fc fuzijskih proteina
|
WO2015116178A1
(en)
*
|
2014-01-31 |
2015-08-06 |
Thomas Jefferson University |
Fusion proteins for modulating regulatory and effector t cells
|
EP2951199A4
(en)
|
2013-01-31 |
2016-07-20 |
Univ Jefferson |
Fusion proteins for the modulation of regulatory and effector T cells
|
UY35468A
(es)
|
2013-03-16 |
2014-10-31 |
Novartis Ag |
Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19
|
EP3783017A1
(en)
|
2013-04-02 |
2021-02-24 |
Chugai Seiyaku Kabushiki Kaisha |
Fc region variant
|
BR112016002614B8
(pt)
|
2013-08-08 |
2023-11-07 |
Hopitaux Paris Assist Publique |
Imunocitoquina e composição farmacêutica
|
AR097306A1
(es)
*
|
2013-08-20 |
2016-03-02 |
Merck Sharp & Dohme |
Modulación de la inmunidad tumoral
|
TW201605896A
(zh)
*
|
2013-08-30 |
2016-02-16 |
安美基股份有限公司 |
Gitr抗原結合蛋白
|
EP3044323B1
(en)
*
|
2013-09-13 |
2022-04-06 |
F. Hoffmann-La Roche AG |
Methods for detecting and quantifying host cell protein in cell lines
|
AU2014318615B2
(en)
|
2013-09-13 |
2020-03-12 |
Genentech, Inc. |
Methods and compositions comprising purified recombinant polypeptides
|
WO2015066413A1
(en)
|
2013-11-01 |
2015-05-07 |
Novartis Ag |
Oxazolidinone hydroxamic acid compounds for the treatment of bacterial infections
|
TWI679976B
(zh)
|
2013-11-13 |
2019-12-21 |
瑞士商諾華公司 |
低及免疫增強劑量之mtor抑制劑及其用途
|
CA3225453A1
(en)
|
2013-12-19 |
2015-06-25 |
Novartis Ag |
Human mesothelin chimeric antigen receptors and uses thereof
|
SMT201800643T1
(it)
|
2013-12-24 |
2019-01-11 |
Bristol Myers Squibb Co |
Composti triciclici come agenti anticancro
|
JO3517B1
(ar)
|
2014-01-17 |
2020-07-05 |
Novartis Ag |
ان-ازاسبيرو الكان حلقي كبديل مركبات اريل-ان مغايرة وتركيبات لتثبيط نشاط shp2
|
JOP20200094A1
(ar)
|
2014-01-24 |
2017-06-16 |
Dana Farber Cancer Inst Inc |
جزيئات جسم مضاد لـ pd-1 واستخداماتها
|
JOP20200096A1
(ar)
|
2014-01-31 |
2017-06-16 |
Children’S Medical Center Corp |
جزيئات جسم مضاد لـ tim-3 واستخداماتها
|
KR20240110004A
(ko)
|
2014-03-14 |
2024-07-12 |
노파르티스 아게 |
Lag-3에 대한 항체 분자 및 그의 용도
|
WO2015142675A2
(en)
|
2014-03-15 |
2015-09-24 |
Novartis Ag |
Treatment of cancer using chimeric antigen receptor
|
DK3511328T3
(da)
|
2014-03-24 |
2021-03-22 |
Novartis Ag |
Organiske monobactam-forbindelser til behandling af bakterieinfektioner
|
DK3888674T3
(da)
|
2014-04-07 |
2024-07-08 |
Novartis Ag |
Behandling af cancer ved anvendelse af anti-cd19-kimær antigenreceptor
|
DK3148579T3
(da)
|
2014-05-28 |
2021-03-08 |
Agenus Inc |
Anti-gitr antistoffer og fremgangsmåder til anvendelse deraf
|
US10987322B2
(en)
|
2014-06-06 |
2021-04-27 |
Flexus Biosciences, Inc. |
Immunoregulatory agents
|
SI3151921T1
(sl)
|
2014-06-06 |
2019-12-31 |
Bristol-Myers Squibb Company |
Protitelesa proti z glukortikoidom induciranim receptorjem za faktor nekroze tumorja(GITR) in njihova uporaba
|
AU2015292744C1
(en)
|
2014-07-21 |
2021-01-21 |
Novartis Ag |
Treatment of cancer using humanized anti-BCMA chimeric antigen receptor
|
JP2017528433A
(ja)
|
2014-07-21 |
2017-09-28 |
ノバルティス アーゲー |
低い免疫増強用量のmTOR阻害剤とCARの組み合わせ
|
WO2016014553A1
(en)
|
2014-07-21 |
2016-01-28 |
Novartis Ag |
Sortase synthesized chimeric antigen receptors
|
EP3172234B1
(en)
|
2014-07-21 |
2020-04-08 |
Novartis AG |
Treatment of cancer using a cd33 chimeric antigen receptor
|
EP3660042B1
(en)
|
2014-07-31 |
2023-01-11 |
Novartis AG |
Subset-optimized chimeric antigen receptor-containing t-cells
|
CN107001316A
(zh)
|
2014-08-06 |
2017-08-01 |
诺华股份有限公司 |
作为抗菌剂的喹诺酮衍生物
|
JP6919118B2
(ja)
|
2014-08-14 |
2021-08-18 |
ノバルティス アーゲー |
GFRα−4キメラ抗原受容体を用いる癌の治療
|
JP2017526356A
(ja)
*
|
2014-08-15 |
2017-09-14 |
オンコメッド ファーマシューティカルズ インコーポレイテッド |
Rspo1結合剤およびその使用
|
HUE049218T2
(hu)
|
2014-08-19 |
2020-10-28 |
Novartis Ag |
Anti-CD123 kiméra antigénreceptor (CAR) rák kezelésében történõ alkalmazásra
|
US20170269076A1
(en)
|
2014-08-27 |
2017-09-21 |
Dana-Farber Cancer Institute, Inc. |
Intracellular osteopontin regulates the lineage commitment of lymphoid subsets
|
ES2771926T3
(es)
|
2014-09-13 |
2020-07-07 |
Novartis Ag |
Terapias de combinación
|
JP2017528523A
(ja)
|
2014-09-16 |
2017-09-28 |
オンコメッド ファーマシューティカルズ インコーポレイテッド |
線維性疾患の治療
|
MX2017003645A
(es)
|
2014-09-17 |
2017-05-30 |
Novartis Ag |
Direccion de celulas citotoxicas con receptores quimericos para inmunoterapia adoptiva.
|
WO2016054555A2
(en)
|
2014-10-03 |
2016-04-07 |
Novartis Ag |
Combination therapies
|
KR20170062485A
(ko)
*
|
2014-10-03 |
2017-06-07 |
다나-파버 캔서 인스티튜트 인크. |
글루코코티코이드-유도 종양 괴사 인자 수용체(gitr) 항체 및 이의 사용 방법
|
CN114107424A
(zh)
|
2014-10-08 |
2022-03-01 |
诺华股份有限公司 |
预测针对嵌合抗原受体疗法的治疗应答性的生物标志及其用途
|
MA41044A
(fr)
*
|
2014-10-08 |
2017-08-15 |
Novartis Ag |
Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer
|
US9988452B2
(en)
|
2014-10-14 |
2018-06-05 |
Novartis Ag |
Antibody molecules to PD-L1 and uses thereof
|
KR102746415B1
(ko)
|
2014-10-29 |
2024-12-26 |
바이시클러드 리미티드 |
Mt1-mmp에 특이적인 바이사이클릭 펩타이드 리간드
|
UY36390A
(es)
|
2014-11-05 |
2016-06-01 |
Flexus Biosciences Inc |
Compuestos moduladores de la enzima indolamina 2,3-dioxigenasa (ido), sus métodos de síntesis y composiciones farmacéuticas que los contienen
|
AR102537A1
(es)
|
2014-11-05 |
2017-03-08 |
Flexus Biosciences Inc |
Agentes inmunomoduladores
|
EP3215141A4
(en)
|
2014-11-05 |
2018-06-06 |
Flexus Biosciences, Inc. |
Immunoregulatory agents
|
HUE052526T2
(hu)
|
2014-11-21 |
2021-05-28 |
Bristol Myers Squibb Co |
Antitestek, amelyek tartalmaznak módosított nehéz konstans régiókat
|
BR112017010110A2
(pt)
|
2014-11-21 |
2018-01-30 |
Bristol-Myers Squibb Company |
anticorpos contra cd73 e usos do mesmo
|
WO2016090034A2
(en)
|
2014-12-03 |
2016-06-09 |
Novartis Ag |
Methods for b cell preconditioning in car therapy
|
RS59507B1
(sr)
|
2014-12-16 |
2019-12-31 |
Novartis Ag |
Jedinjenja izoksazol hidroksamske kiseline kao inhibitori lpxc
|
PE20221834A1
(es)
|
2014-12-19 |
2022-11-29 |
Chugai Pharmaceutical Co Ltd |
Anticuerpos antimiostatina
|
EP3233918A1
(en)
|
2014-12-19 |
2017-10-25 |
Novartis AG |
Combination therapies
|
TW201630907A
(zh)
|
2014-12-22 |
2016-09-01 |
必治妥美雅史谷比公司 |
TGFβR拮抗劑
|
SG10202006538TA
(en)
|
2014-12-23 |
2020-08-28 |
Bristol Myers Squibb Co |
Antibodies to tigit
|
EP3240803B1
(en)
|
2014-12-29 |
2021-11-24 |
Novartis AG |
Methods of making chimeric antigen receptor-expressing cells
|
US11161907B2
(en)
|
2015-02-02 |
2021-11-02 |
Novartis Ag |
Car-expressing cells against multiple tumor antigens and uses thereof
|
MA41460A
(fr)
|
2015-02-03 |
2017-12-12 |
Oncomed Pharm Inc |
Agents de liaison à la tnfrsf et leurs utilisations
|
JP2018510842A
(ja)
|
2015-02-05 |
2018-04-19 |
中外製薬株式会社 |
イオン濃度依存的抗原結合ドメインを含む抗体、Fc領域改変体、IL−8に結合する抗体、およびその使用
|
US10983128B2
(en)
|
2015-02-05 |
2021-04-20 |
Bristol-Myers Squibb Company |
CXCL11 and SMICA as predictive biomarkers for efficacy of anti-CTLA4 immunotherapy
|
AR103726A1
(es)
*
|
2015-02-27 |
2017-05-31 |
Merck Sharp & Dohme |
Cristales de anticuerpos monoclonales anti-pd-1 humanos
|
PE20171789A1
(es)
|
2015-03-02 |
2017-12-28 |
Bristol Myers Squibb Co |
Inhibidores del factor beta de crecimiento de transformacion (tgf-beta)
|
PE20171448A1
(es)
|
2015-03-10 |
2017-10-02 |
Aduro Biotech Inc |
Composiciones y metodos para activar la senalizacion dependiente del estimulador del gen de interferon
|
UY36601A
(es)
|
2015-04-03 |
2016-09-30 |
Bristol Myers Squibb Company Una Corporación Del Estado De Delaware |
Inhibidores de la función enzimática de la indolamina-2,3-dioxigenasa (ido) y composiciones farmacéuticas que los contienen
|
ES2876974T3
(es)
|
2015-04-07 |
2021-11-15 |
Novartis Ag |
Combinación de terapia con receptor de antígeno quimérico y derivados de amino pirimidina
|
RU2021121771A
(ru)
|
2015-04-08 |
2022-01-12 |
Новартис Аг |
Cd20 терапия, cd22 терапия и комбинированная терапия клетками, экспрессирующими химерный антигенный рецептор (car) к cd19
|
WO2016162505A1
(en)
|
2015-04-08 |
2016-10-13 |
F-Star Biotechnology Limited |
Her2 binding agent therapies
|
CN114681608A
(zh)
|
2015-04-13 |
2022-07-01 |
戊瑞治疗有限公司 |
癌症组合疗法
|
GB201506411D0
(en)
|
2015-04-15 |
2015-05-27 |
Bergenbio As |
Humanized anti-axl antibodies
|
EP4234685A3
(en)
|
2015-04-17 |
2023-09-06 |
Novartis AG |
Methods for improving the efficacy and expansion of chimeric antigen receptor-expressing cells
|
EA201792273A1
(ru)
|
2015-04-17 |
2018-04-30 |
Бристол-Маерс Сквибб Компани |
Композиции, содержащие комбинацию анти-pd-1 антитела и другого антитела
|
WO2016172583A1
(en)
|
2015-04-23 |
2016-10-27 |
Novartis Ag |
Treatment of cancer using chimeric antigen receptor and protein kinase a blocker
|
WO2016183114A1
(en)
|
2015-05-11 |
2016-11-17 |
Bristol-Myers Squibb Company |
Tricyclic compounds as anticancer agents
|
US9725449B2
(en)
|
2015-05-12 |
2017-08-08 |
Bristol-Myers Squibb Company |
Tricyclic compounds as anticancer agents
|
CN107849148B
(zh)
|
2015-05-21 |
2023-09-19 |
哈普恩治疗公司 |
三特异性结合蛋白质及使用方法
|
MX2017015260A
(es)
|
2015-06-03 |
2018-02-19 |
Squibb Bristol Myers Co |
Anticuerpos anti receptor de factor de necrosis tumoral inducible por glucocorticoide (gitr) para diagnostico del cancer.
|
WO2016196912A1
(en)
*
|
2015-06-03 |
2016-12-08 |
Dana-Farber Cancer Institute, Inc. |
Methods to induce conversion of regulatory t cells into effector t cells for cancer immunotherapy
|
CN107922500A
(zh)
|
2015-06-29 |
2018-04-17 |
洛克菲勒大学 |
具有增强的激动剂活性的抗cd40抗体
|
WO2017009843A2
(en)
|
2015-07-16 |
2017-01-19 |
Biokine Therapeutics Ltd. |
Compositions, articles of manufacture and methods for treating cancer
|
TWI859112B
(zh)
|
2015-07-21 |
2024-10-21 |
瑞士商諾華公司 |
改良免疫細胞之功效及擴展之方法
|
RU2753439C2
(ru)
*
|
2015-07-23 |
2021-08-16 |
Инхибркс, Инк. |
Поливалетные и полиспецифичные gitr-связывающие слитые белки
|
WO2017019757A1
(en)
|
2015-07-28 |
2017-02-02 |
Bristol-Myers Squibb Company |
Tgf beta receptor antagonists
|
EP3878465A1
(en)
|
2015-07-29 |
2021-09-15 |
Novartis AG |
Combination therapies comprising antibody molecules to tim-3
|
EP3328418A1
(en)
|
2015-07-29 |
2018-06-06 |
Novartis AG |
Combination therapies comprising antibody molecules to pd-1
|
US20180340025A1
(en)
|
2015-07-29 |
2018-11-29 |
Novartis Ag |
Combination therapies comprising antibody molecules to lag-3
|
KR20180042370A
(ko)
|
2015-08-25 |
2018-04-25 |
브리스톨-마이어스 스큅 컴퍼니 |
Tgf 베타 수용체 길항제
|
US11747346B2
(en)
|
2015-09-03 |
2023-09-05 |
Novartis Ag |
Biomarkers predictive of cytokine release syndrome
|
MX390633B
(es)
|
2015-09-14 |
2025-03-04 |
Infinity Pharmaceuticals Inc |
Formas solidas de derivados de isoquinolinona, proceso de fabricacion, composiciones que las contienen y metodos de uso de las mismas.
|
US20190022092A1
(en)
|
2015-09-15 |
2019-01-24 |
Acerta Pharma B.V. |
Therapeutic Combinations of a BTK Inhibitor and a GITR Binding Molecule, a 4-1BB Agonist, or an OX40 Agonist
|
CN108473579B
(zh)
*
|
2015-10-22 |
2022-03-01 |
埃博灵克斯股份有限公司 |
Gitr激动剂
|
EP3371208B8
(en)
|
2015-11-02 |
2024-10-23 |
Five Prime Therapeutics, Inc. |
Cd80 extracellular domain polypeptides and their use in cancer treatment
|
WO2017079116A2
(en)
|
2015-11-03 |
2017-05-11 |
Janssen Biotech, Inc. |
Antibodies specifically binding pd-1 and tim-3 and their uses
|
JP6983776B2
(ja)
|
2015-11-19 |
2021-12-17 |
ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company |
グルココルチコイド誘発腫瘍壊死因子受容体(gitr)に対する抗体およびその使用
|
SG11201804134YA
(en)
|
2015-11-23 |
2018-06-28 |
Five Prime Therapeutics Inc |
Fgfr2 inhibitors alone or in combination with immune stimulating agents in cancer treatment
|
TW202134282A
(zh)
|
2015-12-02 |
2021-09-16 |
美商艾吉納斯公司 |
抗體和使用彼之方法
|
KR102738306B1
(ko)
|
2015-12-15 |
2024-12-03 |
브리스톨-마이어스 스큅 컴퍼니 |
Cxcr4 수용체 길항제
|
EP4424322A3
(en)
|
2015-12-17 |
2025-04-16 |
Novartis AG |
Antibody molecules to pd-1 and uses thereof
|
UY37030A
(es)
|
2015-12-18 |
2017-07-31 |
Novartis Ag |
Anticuerpos dirigidos a cd32b y métodos de uso de los mismos
|
WO2017112741A1
(en)
|
2015-12-22 |
2017-06-29 |
Novartis Ag |
Mesothelin chimeric antigen receptor (car) and antibody against pd-l1 inhibitor for combined use in anticancer therapy
|
US11359009B2
(en)
|
2015-12-25 |
2022-06-14 |
Chugai Seiyaku Kabushiki Kaisha |
Anti-myostatin antibodies and methods of use
|
SG11201805449PA
(en)
|
2015-12-28 |
2018-07-30 |
Novartis Ag |
Methods of making chimeric antigen receptor -expressing cells
|
MX2018008592A
(es)
|
2016-01-11 |
2018-12-10 |
Novartis Ag |
Anticuerpos monoclonales humanizados inmunoestimulantes contra interleucina-2 humana, y proteinas de fusion de los mismos.
|
KR20180110131A
(ko)
|
2016-02-19 |
2018-10-08 |
노파르티스 아게 |
항바이러스제로서의 테트라시클릭 피리돈 화합물
|
MX2018010733A
(es)
|
2016-03-04 |
2019-07-04 |
Novartis Ag |
Celulas que expresan multiples moleculas del receptor de antigeno quimerico (car) y usos de las mismas.
|
KR20180118725A
(ko)
|
2016-03-04 |
2018-10-31 |
브리스톨-마이어스 스큅 컴퍼니 |
항-cd73 항체와의 조합 요법
|
TWI742054B
(zh)
*
|
2016-03-08 |
2021-10-11 |
美商健生生物科技公司 |
Gitr抗體,方法及用途
|
CN109476756B
(zh)
|
2016-03-15 |
2022-05-31 |
埃泰美德(香港)有限公司 |
一种多特异性Fab融合蛋白及其用途
|
CN109069638B
(zh)
|
2016-03-24 |
2022-03-29 |
璟尚生物制药公司 |
用于癌症治疗的三特异性抑制剂
|
FI3433257T3
(fi)
|
2016-03-24 |
2024-01-08 |
Novartis Ag |
Alkynyylinukleosidianalogeja ihmisen rinoviruksen estäjinä
|
WO2017180713A1
(en)
|
2016-04-13 |
2017-10-19 |
Orimabs Ltd. |
Anti-psma antibodies and use thereof
|
WO2017192844A1
(en)
|
2016-05-04 |
2017-11-09 |
Bristol-Myers Squibb Company |
Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
|
US10696648B2
(en)
|
2016-05-04 |
2020-06-30 |
Bristol-Myers Squibb Company |
Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
|
JP2019516681A
(ja)
|
2016-05-04 |
2019-06-20 |
ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company |
インドールアミン2,3−ジオキシゲナーゼ阻害剤およびその使用方法
|
US10544099B2
(en)
|
2016-05-04 |
2020-01-28 |
Bristol-Myers Squibb Company |
Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
|
US11066383B2
(en)
|
2016-05-04 |
2021-07-20 |
Bristol-Myers Squibb Company |
Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
|
TWI786044B
(zh)
|
2016-05-13 |
2022-12-11 |
美商再生元醫藥公司 |
藉由投予pd-1抑制劑治療皮膚癌之方法
|
ES2912131T3
(es)
|
2016-05-20 |
2022-05-24 |
Biohaven Therapeutics Ltd |
Uso de agentes moduladores del glutamato con inmunoterapias para tratar el cáncer
|
US11623958B2
(en)
|
2016-05-20 |
2023-04-11 |
Harpoon Therapeutics, Inc. |
Single chain variable fragment CD3 binding proteins
|
MY200162A
(en)
|
2016-06-10 |
2023-12-09 |
Regeneron Pharma |
Anti-gitr antibodies and uses thereof
|
CA3026356A1
(en)
|
2016-06-14 |
2017-12-21 |
Novartis Ag |
Crystalline form of (r)-4-(5-(cyclopropylethynyl)isoxazol-3-yl)-n-hydroxy-2-methyl-2-(methylsulfonyl)butanamide as an antibacterial agent
|
WO2017216686A1
(en)
|
2016-06-16 |
2017-12-21 |
Novartis Ag |
8,9-fused 2-oxo-6,7-dihydropyrido-isoquinoline compounds as antivirals
|
WO2017216685A1
(en)
|
2016-06-16 |
2017-12-21 |
Novartis Ag |
Pentacyclic pyridone compounds as antivirals
|
KR102531889B1
(ko)
|
2016-06-20 |
2023-05-17 |
키맵 리미티드 |
항-pd-l1 및 il-2 사이토카인
|
SG10201912456RA
(en)
|
2016-06-24 |
2020-02-27 |
Infinity Pharmaceuticals Inc |
Combination therapies
|
JP2019519536A
(ja)
|
2016-07-01 |
2019-07-11 |
ファイブ プライム セラピューティクス, インコーポレイテッド |
Gitrアゴニストおよびcpgを用いた組み合わせ抗腫瘍療法
|
US11098077B2
(en)
|
2016-07-05 |
2021-08-24 |
Chinook Therapeutics, Inc. |
Locked nucleic acid cyclic dinucleotide compounds and uses thereof
|
SG10201911972QA
(en)
|
2016-07-14 |
2020-02-27 |
Bristol Myers Squibb Co |
Antibodies against tim3 and uses thereof
|
US11365252B2
(en)
|
2016-07-20 |
2022-06-21 |
University Of Utah Research Foundation |
CD229 CAR T cells and methods of use thereof
|
US20190292179A1
(en)
|
2016-07-21 |
2019-09-26 |
Bristol-Myers Squibb Company |
TGF Beta RECEPTOR ANTAGONISTS
|
US11046777B2
(en)
*
|
2016-07-22 |
2021-06-29 |
Dana-Farber Cancer Institute, Inc. |
Glucocorticoid-induced tumor necrosis factor receptor (GITR) antibodies and methods of use thereof
|
KR20230079499A
(ko)
|
2016-08-05 |
2023-06-07 |
추가이 세이야쿠 가부시키가이샤 |
Il-8 관련 질환의 치료용 또는 예방용 조성물
|
CN109843916B
(zh)
|
2016-08-12 |
2023-10-31 |
詹森生物科技公司 |
具有增强的激动活性的Fc工程化抗TNFR超家族成员抗体及其使用方法
|
MA45919A
(fr)
|
2016-08-12 |
2019-06-19 |
Janssen Biotech Inc |
Conception d'anticorps modifiés et d'autres molécules contenant un domaine fc présentant des fonctions d'agonisme et d'effecteur améliorées
|
KR20190040990A
(ko)
|
2016-08-26 |
2019-04-19 |
브리스톨-마이어스 스큅 컴퍼니 |
인돌아민 2,3-디옥시게나제의 억제제 및 그의 사용 방법
|
WO2018047109A1
(en)
|
2016-09-09 |
2018-03-15 |
Novartis Ag |
Polycyclic pyridone compounds as antivirals
|
WO2018057585A1
(en)
|
2016-09-21 |
2018-03-29 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Chimeric antigen receptor (car) that targets chemokine receptor ccr4 and its use
|
JOP20190061A1
(ar)
|
2016-09-28 |
2019-03-26 |
Novartis Ag |
مثبطات بيتا-لاكتاماز
|
SG10201913823VA
(en)
|
2016-10-07 |
2020-03-30 |
Novartis Ag |
Chimeric antigen receptors for the treatment of cancer
|
EA037973B1
(ru)
*
|
2016-10-12 |
2021-06-18 |
Янссен Байотек, Инк. |
Антитела к gitr, способы и применение
|
WO2018073753A1
(en)
|
2016-10-18 |
2018-04-26 |
Novartis Ag |
Fused tetracyclic pyridone compounds as antivirals
|
TWI788307B
(zh)
|
2016-10-31 |
2023-01-01 |
美商艾歐凡斯生物治療公司 |
用於擴增腫瘤浸潤性淋巴細胞之工程化人造抗原呈現細胞
|
MA46770A
(fr)
|
2016-11-09 |
2019-09-18 |
Agenus Inc |
Anticorps anti-ox40, anticorps anti-gitr, et leurs procédés d'utilisation
|
US10660909B2
(en)
|
2016-11-17 |
2020-05-26 |
Syntrix Biosystems Inc. |
Method for treating cancer using chemokine antagonists
|
JOP20190100A1
(ar)
|
2016-11-19 |
2019-05-01 |
Potenza Therapeutics Inc |
بروتينات ربط مولد ضد مضاد لـ gitr وطرق استخدامها
|
KR20190104528A
(ko)
|
2016-12-03 |
2019-09-10 |
주노 쎄러퓨티크스 인코퍼레이티드 |
Car-t 세포들 투여를 결정하는 방법
|
KR102592246B1
(ko)
|
2016-12-22 |
2023-10-23 |
암젠 인크 |
폐암, 췌장암 또는 대장암을 치료하기 위한 kras g12c 억제제로서의 벤즈이소티아졸, 이소티아졸로[3,4-b]피리딘, 퀴나졸린, 프탈라진, 피리도[2,3-d]피리다진 및 피리도[2,3-d]피리미딘 유도체
|
MX2019007019A
(es)
|
2016-12-22 |
2019-08-16 |
Univ Degli Studi Magna Graecia Catanzaro |
Anticuerpo monoclonal dirigido a un epitope de cd43 sialoglicosilado especifico asociado al cancer.
|
WO2018132279A1
(en)
|
2017-01-05 |
2018-07-19 |
Bristol-Myers Squibb Company |
Tgf beta receptor antagonists
|
WO2018128939A1
(en)
|
2017-01-05 |
2018-07-12 |
Gensun Biopharma Inc. |
Checkpoint regulator antagonists
|
BR112019013940A2
(pt)
|
2017-01-06 |
2020-02-11 |
Iovance Biotherapeutics, Inc. |
Método de tratar um câncer com uma população de linfócitos infiltrantes de tumor, processo para preparação de uma população de linfócitos infiltrantes de tumor, população de linfócitos infiltrantes de tumor, e, composição farmacêutica.
|
US10399962B2
(en)
|
2017-01-20 |
2019-09-03 |
Arcus Biosciences, Inc. |
Azolopyrimidine for the treatment of cancer-related disorders
|
WO2018138521A1
(en)
|
2017-01-27 |
2018-08-02 |
Ultrahuman One Limited |
Binding agents
|
SG11201907242TA
(en)
|
2017-02-10 |
2019-09-27 |
Eutilex Co Ltd |
IFN-γ-INDUCIBLE REGULATORY T CELL CONVERTIBLE ANTI-CANCER (IRTCA) ANTIBODY AND USES THEREOF
|
EP3585812A1
(en)
|
2017-02-21 |
2020-01-01 |
Regeneron Pharmaceuticals, Inc. |
Anti-pd-1 antibodies for treatment of lung cancer
|
JP2020510435A
(ja)
*
|
2017-03-03 |
2020-04-09 |
ライナット ニューロサイエンス コーポレイション |
抗gitr抗体およびその使用方法
|
BR112019019795A2
(pt)
|
2017-03-31 |
2020-04-22 |
Bristol-Myers Squibb Company |
métodos para tratar tumor
|
WO2018187227A1
(en)
|
2017-04-03 |
2018-10-11 |
Concologie, Inc. |
Methods for treating cancer using ps-targeting antibodies with immuno-oncology agents
|
WO2018185618A1
(en)
|
2017-04-03 |
2018-10-11 |
Novartis Ag |
Anti-cdh6 antibody drug conjugates and anti-gitr antibody combinations and methods of treatment
|
TWI788340B
(zh)
|
2017-04-07 |
2023-01-01 |
美商必治妥美雅史谷比公司 |
抗icos促效劑抗體及其用途
|
MX2019012465A
(es)
|
2017-04-20 |
2020-07-27 |
Adc Therapeutics Sa |
Terapia combinada con un conjugado de anticuerpo y farmaco anti-cd25.
|
EP3612234B1
(en)
|
2017-04-20 |
2024-03-13 |
ADC Therapeutics SA |
Combination therapy with an anti-axl antibody-drug conjugate
|
BR112019021992A2
(pt)
|
2017-04-21 |
2020-06-09 |
Kyn Therapeutics |
inibidores de ahr de indol e usos dos mesmos
|
US11760777B2
(en)
|
2017-04-26 |
2023-09-19 |
Bristol-Myers Squibb Company |
Methods of antibody production that minimize disulfide bond reduction
|
AR111419A1
(es)
|
2017-04-27 |
2019-07-10 |
Novartis Ag |
Compuestos fusionados de indazol piridona como antivirales
|
US20200179511A1
(en)
|
2017-04-28 |
2020-06-11 |
Novartis Ag |
Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
|
EP3615055A1
(en)
|
2017-04-28 |
2020-03-04 |
Novartis AG |
Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor
|
EP3628070B1
(en)
|
2017-04-28 |
2021-09-08 |
Five Prime Therapeutics, Inc. |
Cd80 extracellular domain polypeptides for use in increasing central memory t cells
|
AR111651A1
(es)
|
2017-04-28 |
2019-08-07 |
Novartis Ag |
Conjugados de anticuerpos que comprenden agonistas del receptor de tipo toll y terapias de combinación
|
UY37695A
(es)
|
2017-04-28 |
2018-11-30 |
Novartis Ag |
Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo
|
EA039583B1
(ru)
*
|
2017-05-02 |
2022-02-14 |
Регенерон Фармасьютикалз, Инк. |
Антитела против gitr и их применения
|
RU2019138507A
(ru)
|
2017-05-02 |
2021-06-02 |
Мерк Шарп И Доум Корп. |
Составы антител против lag3 и совместные составы антител против lag3 и антител против pd-1
|
JOP20190260A1
(ar)
|
2017-05-02 |
2019-10-31 |
Merck Sharp & Dohme |
صيغ ثابتة لأجسام مضادة لمستقبل الموت المبرمج 1 (pd-1) وطرق استخدامها
|
UY37718A
(es)
|
2017-05-05 |
2018-11-30 |
Novartis Ag |
2-quinolinonas triciclicas como agentes antibacteriales
|
US10543271B2
(en)
|
2017-05-12 |
2020-01-28 |
Harpoon Therapeutics, Inc. |
Mesothelin binding proteins
|
WO2018209049A1
(en)
|
2017-05-12 |
2018-11-15 |
Bristol-Myers Squibb Company |
Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
|
EP3625260A1
(en)
|
2017-05-16 |
2020-03-25 |
Bristol-Myers Squibb Company |
Treatment of cancer with anti-gitr agonist antibodies
|
JP7189155B2
(ja)
|
2017-05-17 |
2022-12-13 |
アーカス バイオサイエンシズ インコーポレイティド |
癌関連障害の治療のためのキナゾリン-ピラゾール誘導体
|
JOP20190272A1
(ar)
|
2017-05-22 |
2019-11-21 |
Amgen Inc |
مثبطات kras g12c وطرق لاستخدامها
|
KR20220167342A
(ko)
|
2017-05-25 |
2022-12-20 |
브리스톨-마이어스 스큅 컴퍼니 |
변형된 중쇄 불변 영역을 포함하는 항체
|
WO2018223004A1
(en)
|
2017-06-01 |
2018-12-06 |
Xencor, Inc. |
Bispecific antibodies that bind cd20 and cd3
|
JP2020522498A
(ja)
|
2017-06-01 |
2020-07-30 |
ゼンコー・インコーポレイテッドXencor、 Inc. |
Cd123 cd3に結合する二重特異性抗体
|
BR112019025403A2
(pt)
|
2017-06-02 |
2020-08-18 |
Juno Therapeutics Inc |
artigos de fabricação e métodos para tratamento usando terapia celular adotiva
|
WO2018226336A1
(en)
|
2017-06-09 |
2018-12-13 |
Providence Health & Services - Oregon |
Utilization of cd39 and cd103 for identification of human tumor reactive cells for treatment of cancer
|
ES2988683T3
(es)
|
2017-06-14 |
2024-11-21 |
Adc Therapeutics Sa |
Pautas posológicas para la administración de un CAF anti-CD19
|
WO2018229715A1
(en)
|
2017-06-16 |
2018-12-20 |
Novartis Ag |
Compositions comprising anti-cd32b antibodies and methods of use thereof
|
CN109136275B
(zh)
|
2017-06-19 |
2021-03-16 |
百奥赛图(北京)医药科技股份有限公司 |
人源化gitr基因改造动物模型的制备方法及应用
|
EP3642240A1
(en)
|
2017-06-22 |
2020-04-29 |
Novartis AG |
Antibody molecules to cd73 and uses thereof
|
JP2020524694A
(ja)
|
2017-06-22 |
2020-08-20 |
ノバルティス アーゲー |
がんの処置における使用のためのIL−1β結合性抗体
|
WO2018235056A1
(en)
|
2017-06-22 |
2018-12-27 |
Novartis Ag |
Il-1beta binding antibodies for use in treating cancer
|
MX2019015885A
(es)
|
2017-06-22 |
2020-09-10 |
Novartis Ag |
Moleculas de anticuerpo que se unen a cd73 y usos de las mismas.
|
CN111050791A
(zh)
|
2017-06-27 |
2020-04-21 |
诺华股份有限公司 |
用于抗tim-3抗体的给药方案及其用途
|
US20220225597A1
(en)
|
2017-06-29 |
2022-07-21 |
Juno Therapeutics, Inc. |
Mouse model for assessing toxicities associated with immunotherapies
|
JP2020532279A
(ja)
|
2017-06-30 |
2020-11-12 |
江▲蘇▼恒瑞医▲薬▼股▲フン▼有限公司Jiangsu Hengrui Medicine Co., Ltd. |
抗gitr抗体、その抗原結合性断片、およびその医薬用途
|
CA3066789A1
(en)
|
2017-06-30 |
2019-01-03 |
Bristol-Myers Squibb Company |
Amorphous and crystalline forms of ido inhibitors
|
CA3070095A1
(en)
|
2017-07-20 |
2019-01-24 |
Novartis Ag |
Dosage regimens of anti-lag-3 antibodies and uses thereof
|
EP3658565B1
(en)
|
2017-07-28 |
2022-11-09 |
Bristol-Myers Squibb Company |
Cyclic dinucleotides as anticancer agents
|
CN111183147B
(zh)
|
2017-08-04 |
2024-07-05 |
拜斯科技术开发有限公司 |
Cd137特异性的双环肽配体
|
BR112020003116A2
(pt)
|
2017-08-17 |
2020-08-04 |
Ikena Oncology, Inc. |
inibidores de ahr e usos dos mesmos
|
EP3672990A1
(en)
|
2017-08-25 |
2020-07-01 |
Five Prime Therapeutics, Inc. |
B7-h4 antibodies and methods of use thereof
|
CN111051328B
(zh)
|
2017-08-31 |
2023-11-03 |
百时美施贵宝公司 |
作为抗癌剂的环二核苷酸
|
WO2019046496A1
(en)
|
2017-08-31 |
2019-03-07 |
Bristol-Myers Squibb Company |
CYCLIC DINUCLEOTIDES AS ANTICANCER AGENTS
|
WO2019046498A1
(en)
|
2017-08-31 |
2019-03-07 |
Bristol-Myers Squibb Company |
CYCLIC DINUCLEOTIDES AS ANTICANCER AGENTS
|
UY37870A
(es)
|
2017-09-08 |
2019-03-29 |
Amgen Inc |
Inhibidores de kras g12c y métodos para utilizarlos campo de la invención
|
IL295603B2
(en)
|
2017-09-22 |
2024-03-01 |
Kymera Therapeutics Inc |
Protein degraders and uses thereof
|
US11358948B2
(en)
|
2017-09-22 |
2022-06-14 |
Kymera Therapeutics, Inc. |
CRBN ligands and uses thereof
|
WO2019074824A1
(en)
|
2017-10-09 |
2019-04-18 |
Bristol-Myers Squibb Company |
INDOLEAMINE 2,3-DIOXYGENASE INHIBITORS AND METHODS OF USE
|
US11649212B2
(en)
|
2017-10-09 |
2023-05-16 |
Bristol-Myers Squibb Company |
Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
|
WO2019074887A1
(en)
|
2017-10-10 |
2019-04-18 |
Bristol-Myers Squibb Company |
CYCLIC DINUCLEOTIDES AS ANTICANCER AGENTS
|
SI3694529T1
(sl)
|
2017-10-13 |
2024-10-30 |
Harpoon Therapeutics, Inc. |
Trispecifične beljakovine in načini uporabe
|
IL315737A
(en)
|
2017-10-13 |
2024-11-01 |
Harpoon Therapeutics Inc |
B-cell maturation antigen-binding proteins
|
CN111247169A
(zh)
|
2017-10-15 |
2020-06-05 |
百时美施贵宝公司 |
治疗肿瘤的方法
|
WO2019079261A1
(en)
|
2017-10-16 |
2019-04-25 |
Bristol-Myers Squibb Company |
CYCLIC DINUCLEOTIDES AS ANTICANCER AGENTS
|
WO2019081983A1
(en)
|
2017-10-25 |
2019-05-02 |
Novartis Ag |
CD32B TARGETING ANTIBODIES AND METHODS OF USE
|
SG11202003177RA
(en)
|
2017-10-25 |
2020-05-28 |
Novartis Ag |
Methods of making chimeric antigen receptor-expressing cells
|
US12031975B2
(en)
|
2017-11-01 |
2024-07-09 |
Juno Therapeutics, Inc. |
Methods of assessing or monitoring a response to a cell therapy
|
ES3003809T3
(en)
|
2017-11-01 |
2025-03-11 |
Juno Therapeutics Inc |
Chimeric antigen receptors specific for b-cell maturation antigen and encoding polynucleotides
|
MX2020004243A
(es)
|
2017-11-01 |
2020-09-25 |
Juno Therapeutics Inc |
Receptores de anticuerpos y de antigenos quimericos especificos para el antigeno de maduracion de celulas b.
|
CN111527084B
(zh)
|
2017-11-06 |
2023-07-18 |
百时美施贵宝公司 |
可用作hpk1抑制剂的异呋喃酮化合物
|
AU2018368731A1
(en)
|
2017-11-16 |
2020-05-14 |
Novartis Ag |
Combination therapies
|
US20210079015A1
(en)
|
2017-11-17 |
2021-03-18 |
Novartis Ag |
Novel dihydroisoxazole compounds and their use for the treatment of hepatitis b
|
MA51210A
(fr)
|
2017-12-01 |
2020-10-07 |
Juno Therapeutics Inc |
Procédés de dosage et de modulation de cellules génétiquement modifiées
|
WO2019118937A1
(en)
|
2017-12-15 |
2019-06-20 |
Juno Therapeutics, Inc. |
Anti-cct5 binding molecules and methods of use thereof
|
EP3728266A1
(en)
|
2017-12-20 |
2020-10-28 |
Novartis AG |
Fused tricyclic pyrazolo-dihydropyrazinyl-pyridone compounds as antivirals
|
IL315310A
(en)
|
2017-12-26 |
2024-10-01 |
Kymera Therapeutics Inc |
Irak degraders and uses thereof
|
JP7284759B2
(ja)
|
2017-12-27 |
2023-05-31 |
ブリストル-マイヤーズ スクイブ カンパニー |
抗cd40抗体およびその使用
|
US11447449B2
(en)
|
2018-01-05 |
2022-09-20 |
Bristol-Myers Squibb Company |
Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
|
EP3737666A4
(en)
|
2018-01-12 |
2022-01-05 |
Kymera Therapeutics, Inc. |
PROTEIN DEGRADATION AGENTS AND ASSOCIATED USES
|
US12129297B2
(en)
|
2018-01-12 |
2024-10-29 |
Bristol-Myers Squibb Company |
Antibodies against TIM3 and uses thereof
|
WO2019140387A1
(en)
|
2018-01-12 |
2019-07-18 |
Kymera Therapeutics, Inc. |
Crbn ligands and uses thereof
|
US12398209B2
(en)
|
2018-01-22 |
2025-08-26 |
Janssen Biotech, Inc. |
Methods of treating cancers with antagonistic anti-PD-1 antibodies
|
EP3746071A4
(en)
|
2018-01-29 |
2021-09-01 |
Merck Patent GmbH |
GCN2 INHIBITORS AND THEIR USES
|
SG11202006701TA
(en)
|
2018-01-29 |
2020-08-28 |
Merck Patent Gmbh |
Gcn2 inhibitors and uses thereof
|
US10519187B2
(en)
|
2018-02-13 |
2019-12-31 |
Bristol-Myers Squibb Company |
Cyclic dinucleotides as anticancer agents
|
US20210137930A1
(en)
|
2018-02-13 |
2021-05-13 |
Iovance Biotherapeutics, Inc. |
Expansion of tumor infiltrating lymphocytes (tils) with adenosine a2a receptor antagonists and therapeutic combinations of tils and adenosine a2a receptor antagonists
|
WO2019165315A1
(en)
|
2018-02-23 |
2019-08-29 |
Syntrix Biosystems Inc. |
Method for treating cancer using chemokine antagonists alone or in combination
|
PH12020551213A1
(en)
|
2018-02-23 |
2021-04-19 |
Bicycletx Ltd |
Multimeric bicyclic peptide ligands
|
CN111801331A
(zh)
|
2018-02-28 |
2020-10-20 |
诺华股份有限公司 |
吲哚-2-羰基化合物及其用于治疗乙型肝炎的用途
|
JP2021516051A
(ja)
|
2018-03-02 |
2021-07-01 |
ファイブ プライム セラピューティクス, インコーポレイテッド |
B7−h4抗体及びその使用方法
|
IL276813B2
(en)
|
2018-03-05 |
2024-09-01 |
Arcus Biosciences Inc |
4-SUBSTITUTED-5-AMINO-OCTAHYDROCYCLOPENTA[c]PYRROLE-5-CARBOXYLIC ACID DERIVATIVES, PHARMACEUTICAL COMBINATIONS THEREOF AND USE THEREOF IN TREATMENT OF DISEASES
|
EP3762397B1
(en)
|
2018-03-08 |
2024-05-01 |
Bristol-Myers Squibb Company |
Cyclic dinucleotides as anticancer agents
|
CN111971304A
(zh)
|
2018-03-21 |
2020-11-20 |
戊瑞治疗有限公司 |
在酸性pH结合至VISTA的抗体
|
EP3768715A1
(en)
|
2018-03-23 |
2021-01-27 |
Bristol-Myers Squibb Company |
Antibodies against mica and/or micb and uses thereof
|
CN110357958A
(zh)
*
|
2018-03-26 |
2019-10-22 |
信达生物制药(苏州)有限公司 |
抗糖皮质激素诱导的肿瘤坏死因子受体(gitr)的小型化抗体、其聚合物及应用
|
CN110305210B
(zh)
|
2018-03-27 |
2023-02-28 |
信达生物制药(苏州)有限公司 |
新型抗体分子、其制备方法及其用途
|
WO2019184909A1
(zh)
|
2018-03-27 |
2019-10-03 |
信达生物制药(苏州)有限公司 |
新型抗体分子、其制备方法及其用途
|
KR102825164B1
(ko)
|
2018-03-27 |
2025-06-26 |
브리스톨-마이어스 스큅 컴퍼니 |
자외선 신호를 사용한 단백질 농도의 실시간 모니터링
|
JP2021519771A
(ja)
|
2018-03-30 |
2021-08-12 |
ブリストル−マイヤーズ スクイブ カンパニーBristol−Myers Squibb Company |
腫瘍を処置する方法
|
US20210147547A1
(en)
|
2018-04-13 |
2021-05-20 |
Novartis Ag |
Dosage Regimens For Anti-Pd-L1 Antibodies And Uses Thereof
|
CA3096546A1
(en)
|
2018-04-16 |
2019-10-24 |
Arrys Therapeutics, Inc. |
Ep4 inhibitors and use thereof
|
CN110386981A
(zh)
*
|
2018-04-20 |
2019-10-29 |
信达生物制药(苏州)有限公司 |
抗gitr抗体及其用途
|
US20210047405A1
(en)
|
2018-04-27 |
2021-02-18 |
Novartis Ag |
Car t cell therapies with enhanced efficacy
|
EP3788369A1
(en)
|
2018-05-01 |
2021-03-10 |
Novartis Ag |
Biomarkers for evaluating car-t cells to predict clinical outcome
|
US12037323B2
(en)
|
2018-05-03 |
2024-07-16 |
Bristol-Myers Squibb Company |
Uracil derivatives as Mer-AXL inhibitors
|
JP7266043B2
(ja)
|
2018-05-04 |
2023-04-27 |
アムジエン・インコーポレーテツド |
KRas G12C阻害剤及びそれを使用する方法
|
CA3099118A1
(en)
|
2018-05-04 |
2019-11-07 |
Amgen Inc. |
Kras g12c inhibitors and methods of using the same
|
AU2019265822B2
(en)
|
2018-05-10 |
2024-07-18 |
Amgen Inc. |
KRAS G12C inhibitors for the treatment of cancer
|
WO2019224275A1
(en)
|
2018-05-23 |
2019-11-28 |
Adc Therapeutics Sa |
Molecular adjuvant
|
WO2019227003A1
(en)
|
2018-05-25 |
2019-11-28 |
Novartis Ag |
Combination therapy with chimeric antigen receptor (car) therapies
|
AR126019A1
(es)
|
2018-05-30 |
2023-09-06 |
Novartis Ag |
Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación
|
US20210214459A1
(en)
|
2018-05-31 |
2021-07-15 |
Novartis Ag |
Antibody molecules to cd73 and uses thereof
|
CN112512578A
(zh)
|
2018-06-01 |
2021-03-16 |
诺华股份有限公司 |
结合cd123和cd3的双特异性抗体的给药
|
MA52765A
(fr)
|
2018-06-01 |
2021-04-14 |
Amgen Inc |
Inhibiteurs de kras g12c et leurs procédés d'utilisation
|
MA52780A
(fr)
|
2018-06-11 |
2021-04-14 |
Amgen Inc |
Inhibiteurs de kras g12c pour le traitement du cancer
|
CA3100390A1
(en)
|
2018-06-12 |
2020-03-12 |
Amgen Inc. |
Kras g12c inhibitors encompassing piperazine ring and use thereof in the treatment of cancer
|
MX2020013443A
(es)
|
2018-06-13 |
2021-02-26 |
Novartis Ag |
Receptores de antigeno quimerico de bcma y usos de los mismos.
|
WO2019241730A2
(en)
|
2018-06-15 |
2019-12-19 |
Flagship Pioneering Innovations V, Inc. |
Increasing immune activity through modulation of postcellular signaling factors
|
IL279489B1
(en)
|
2018-06-22 |
2025-06-01 |
Bicycletx Ltd |
Bicyclic peptide ligands specific for nectin-4, a drug conjugate comprising the peptide ligand and a pharmaceutical composition comprising the drug conjugate
|
SG11202012972YA
(en)
|
2018-06-27 |
2021-01-28 |
Bristol Myers Squibb Co |
Substituted naphthyridinone compounds useful as t cell activators
|
HRP20230627T1
(hr)
|
2018-06-27 |
2023-09-29 |
Bristol-Myers Squibb Company |
Spojevi naftiridinona korisni kao aktivatori t ćelija
|
CN113056285B
(zh)
|
2018-06-29 |
2025-02-07 |
璟尚生物制药公司 |
抗肿瘤免疫检查点调节剂拮抗剂
|
US11292792B2
(en)
|
2018-07-06 |
2022-04-05 |
Kymera Therapeutics, Inc. |
Tricyclic CRBN ligands and uses thereof
|
TW202428604A
(zh)
|
2018-07-09 |
2024-07-16 |
美商戊瑞治療有限公司 |
結合至ilt4的抗體
|
AR116109A1
(es)
|
2018-07-10 |
2021-03-31 |
Novartis Ag |
Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
|
CN112261970B
(zh)
|
2018-07-10 |
2025-02-07 |
诺华股份有限公司 |
3-(5-羟基-1-氧代异吲哚啉-2-基)哌啶-2,6-二酮衍生物及其在治疗ikaros家族锌指2(ikzf2)依赖性疾病中的用途
|
JP7700036B2
(ja)
|
2018-07-11 |
2025-06-30 |
ファイヴ プライム セラピューティクス インク |
酸性pHでVISTAと結合する抗体
|
CA3106366A1
(en)
|
2018-07-18 |
2020-01-23 |
Arcus Biosciences, Inc. |
Solid forms of an azolopyrimidine compound
|
US12059420B2
(en)
|
2018-07-23 |
2024-08-13 |
Bristol-Myers Squibb Company |
Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
|
US12145927B2
(en)
|
2018-07-23 |
2024-11-19 |
Bristol-Myers Squibb Company |
Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
|
CN112789294A
(zh)
|
2018-07-24 |
2021-05-11 |
印希比股份有限公司 |
含有受限cd3结合结构域和受体结合区的多特异性多肽构建体及其使用方法
|
WO2020021465A1
(en)
|
2018-07-25 |
2020-01-30 |
Advanced Accelerator Applications (Italy) S.R.L. |
Method of treatment of neuroendocrine tumors
|
US12064433B2
(en)
|
2018-07-27 |
2024-08-20 |
Arcus Biosciences, Inc. |
Pyridone A2R antagonists
|
US10959986B2
(en)
|
2018-08-29 |
2021-03-30 |
Bristol-Myers Squibb Company |
Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
|
US11253525B2
(en)
|
2018-08-29 |
2022-02-22 |
Bristol-Myers Squibb Company |
Inhibitors of indoleamine 2,3-dioxygenase and methods of their use
|
KR20210055046A
(ko)
|
2018-08-31 |
2021-05-14 |
노파르티스 아게 |
키메라 항원 수용체 발현 세포의 제조 방법
|
WO2020047449A2
(en)
|
2018-08-31 |
2020-03-05 |
Novartis Ag |
Methods of making chimeric antigen receptor-expressing cells
|
US12030875B2
(en)
|
2018-09-07 |
2024-07-09 |
PIC Therapeutics, Inc. |
EIF4E inhibitors and uses thereof
|
JP7654539B2
(ja)
|
2018-09-07 |
2025-04-01 |
ファイザー・インク |
抗αvβ8抗体、組成物及びその使用
|
CN112996789A
(zh)
|
2018-09-12 |
2021-06-18 |
诺华股份有限公司 |
抗病毒吡啶并吡嗪二酮化合物
|
WO2020061482A1
(en)
|
2018-09-21 |
2020-03-26 |
Harpoon Therapeutics, Inc. |
Egfr binding proteins and methods of use
|
JP7425049B2
(ja)
|
2018-09-25 |
2024-01-30 |
ハープーン セラピューティクス,インク. |
Dll3結合タンパク質および使用方法
|
US20220047633A1
(en)
|
2018-09-28 |
2022-02-17 |
Novartis Ag |
Cd22 chimeric antigen receptor (car) therapies
|
US20210347851A1
(en)
|
2018-09-28 |
2021-11-11 |
Novartis Ag |
Cd19 chimeric antigen receptor (car) and cd22 car combination therapies
|
AU2019350592B2
(en)
|
2018-09-29 |
2024-09-26 |
Novartis Ag |
Process of manufacture of a compound for inhibiting the activity of SHP2
|
JP7611820B2
(ja)
|
2018-10-11 |
2025-01-10 |
インヒブルクス バイオサイエンシズ インコーポレイテッド |
Dll3シングルドメイン抗体およびその治療用組成物
|
US11208485B2
(en)
|
2018-10-11 |
2021-12-28 |
Inhibrx, Inc. |
PD-1 single domain antibodies and therapeutic compositions thereof
|
EP3873532A1
(en)
|
2018-10-31 |
2021-09-08 |
Novartis AG |
Dc-sign antibody drug conjugates
|
KR20210102888A
(ko)
|
2018-11-01 |
2021-08-20 |
주노 쎄러퓨티크스 인코퍼레이티드 |
G 단백질 결합 수용체 c 클래스 5 그룹 d 멤버(gprc5d)에 특이적인 키메라 항원 수용체
|
CA3117419A1
(en)
|
2018-11-01 |
2020-05-07 |
Juno Therapeutics, Inc. |
Methods for treatment using chimeric antigen receptors specific for b-cell maturation antigen
|
CA3118144A1
(en)
|
2018-11-07 |
2020-05-14 |
Merck Sharp & Dohme Corp. |
Co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies
|
NZ777032A
(en)
|
2018-11-16 |
2024-07-26 |
Bristol Myers Squibb Co |
Anti-nkg2a antibodies and uses thereof
|
US20220008465A1
(en)
|
2018-11-16 |
2022-01-13 |
Juno Therapeutics, Inc. |
Methods of dosing engineered t cells for the treatment of b cell malignancies
|
JP7516029B2
(ja)
|
2018-11-16 |
2024-07-16 |
アムジエン・インコーポレーテツド |
Kras g12c阻害剤化合物の重要な中間体の改良合成法
|
WO2020102646A2
(en)
|
2018-11-16 |
2020-05-22 |
Arcus Biosciences, Inc. |
Inhibitors of arg1 and/or arg2
|
JP7377679B2
(ja)
|
2018-11-19 |
2023-11-10 |
アムジエン・インコーポレーテツド |
がん治療のためのkrasg12c阻害剤及び1種以上の薬学的に活性な追加の薬剤を含む併用療法
|
WO2020106640A1
(en)
|
2018-11-19 |
2020-05-28 |
Amgen Inc. |
Kras g12c inhibitors and methods of using the same
|
JP2022513653A
(ja)
|
2018-11-28 |
2022-02-09 |
ブリストル-マイヤーズ スクイブ カンパニー |
修飾された重鎖定常領域を含む抗体
|
KR20210111252A
(ko)
|
2018-11-30 |
2021-09-10 |
카이메라 쎄라퓨틱스 인코포레이티드 |
Irak 분해제 및 이의 용도
|
JP7695882B2
(ja)
|
2018-11-30 |
2025-06-19 |
ジュノー セラピューティクス インコーポレイテッド |
養子細胞療法を用いた処置のための方法
|
GB201820288D0
(en)
|
2018-12-13 |
2019-01-30 |
Bicycle Tx Ltd |
Bicycle peptide ligaands specific for MT1-MMP
|
GB201820325D0
(en)
|
2018-12-13 |
2019-01-30 |
Bicyclerd Ltd |
Bicyclic peptide ligands specific for psma
|
AU2019404576B2
(en)
|
2018-12-20 |
2025-07-17 |
Amgen Inc. |
Heteroaryl amides useful as KIF18A inhibitors
|
US20240245670A1
(en)
|
2018-12-20 |
2024-07-25 |
Novartis Ag |
Dosing regimen and pharmaceutical combination comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
|
MA54550A
(fr)
|
2018-12-20 |
2022-03-30 |
Amgen Inc |
Inhibiteurs de kif18a
|
US20220002311A1
(en)
|
2018-12-20 |
2022-01-06 |
Amgen Inc. |
Kif18a inhibitors
|
EP3670659A1
(en)
|
2018-12-20 |
2020-06-24 |
Abivax |
Biomarkers, and uses in treatment of viral infections, inflammations, or cancer
|
CA3123871A1
(en)
|
2018-12-20 |
2020-06-25 |
Amgen Inc. |
Kif18a inhibitors
|
EP3897613A1
(en)
|
2018-12-21 |
2021-10-27 |
Novartis AG |
Use of il-1beta binding antibodies
|
CA3119582A1
(en)
|
2018-12-21 |
2020-06-25 |
Novartis Ag |
Use of il-1.beta. binding antibodies
|
EP3898675A1
(en)
|
2018-12-21 |
2021-10-27 |
Novartis AG |
Use of il-1 beta antibodies in the treatment or prevention of myelodysplastic syndrome
|
WO2020128637A1
(en)
|
2018-12-21 |
2020-06-25 |
Novartis Ag |
Use of il-1 binding antibodies in the treatment of a msi-h cancer
|
AU2020215576A1
(en)
|
2019-01-29 |
2021-07-08 |
Juno Therapeutics, Inc. |
Antibodies and chimeric antigen receptors specific for receptor tyrosine kinase like orphan receptor 1 (ROR1)
|
CA3123519A1
(en)
|
2019-02-15 |
2020-08-20 |
Novartis Ag |
Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
|
CA3124935A1
(en)
|
2019-02-15 |
2020-08-20 |
Novartis Ag |
3-(1-oxo-5-(piperidin-4-yl)isoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
|
WO2020172658A1
(en)
|
2019-02-24 |
2020-08-27 |
Bristol-Myers Squibb Company |
Methods of isolating a protein
|
CA3130080A1
(en)
|
2019-03-01 |
2020-09-10 |
Revolution Medicines, Inc. |
Bicyclic heteroaryl compounds and uses thereof
|
JP2022522778A
(ja)
|
2019-03-01 |
2022-04-20 |
レボリューション メディシンズ インコーポレイテッド |
二環式ヘテロシクリル化合物及びその使用
|
EP3937964A4
(en)
|
2019-03-12 |
2022-11-16 |
Arcus Biosciences, Inc. |
TREATMENT OF ONCOGENE-DRIVEN CANCERS
|
AU2020242284A1
(en)
|
2019-03-19 |
2021-09-16 |
Fundació Privada Institut D'investigació Oncològica De Vall Hebron |
Combination therapy for the treatment of cancer
|
CN114269370A
(zh)
|
2019-03-29 |
2022-04-01 |
迈斯特治疗公司 |
离体产生t细胞治疗剂的方法以及相关的组合物和方法
|
US12310965B2
(en)
|
2019-03-29 |
2025-05-27 |
Arcus Biosciences, Inc. |
Treatment of cancer utilizing an identified adenosine fingerprint
|
JP2022528887A
(ja)
|
2019-04-02 |
2022-06-16 |
バイスクルテクス・リミテッド |
バイシクルトキシンコンジュゲートおよびその使用
|
CN120574283A
(zh)
|
2019-04-05 |
2025-09-02 |
凯麦拉医疗公司 |
Stat降解剂和其用途
|
WO2020210678A1
(en)
|
2019-04-12 |
2020-10-15 |
Novartis Ag |
Methods of making chimeric antigen receptor-expressing cells
|
RU2734432C1
(ru)
*
|
2019-04-23 |
2020-10-16 |
Закрытое Акционерное Общество "Биокад" |
Моноклональное антитело, которое специфически связывается с GITR
|
EP3959320A1
(en)
|
2019-04-24 |
2022-03-02 |
Novartis AG |
Compositions and methods for selective protein degradation
|
WO2020227159A2
(en)
|
2019-05-03 |
2020-11-12 |
Flagship Pioneering Innovations V, Inc. |
Methods of modulating immune activity
|
WO2020231766A1
(en)
|
2019-05-13 |
2020-11-19 |
Bristol-Myers Squibb Company |
AGONISTS OF ROR GAMMAt
|
US12012374B2
(en)
|
2019-05-13 |
2024-06-18 |
Bristol-Myers Squibb Company |
Agonists of ROR GAMMAt
|
EP3738593A1
(en)
|
2019-05-14 |
2020-11-18 |
Amgen, Inc |
Dosing of kras inhibitor for treatment of cancers
|
CN114144414A
(zh)
|
2019-05-21 |
2022-03-04 |
美国安进公司 |
固态形式
|
KR20220012292A
(ko)
|
2019-05-23 |
2022-02-03 |
브리스톨-마이어스 스큅 컴퍼니 |
세포 배양 배지를 모니터링하는 방법
|
JP2022534981A
(ja)
|
2019-05-30 |
2022-08-04 |
ブリストル-マイヤーズ スクイブ カンパニー |
細胞局在化シグネチャーおよび組み合わせ治療
|
KR20220016155A
(ko)
|
2019-05-30 |
2022-02-08 |
브리스톨-마이어스 스큅 컴퍼니 |
면역-종양학 (i-o) 요법에 적합한 대상체를 확인하는 방법
|
JP2022534967A
(ja)
|
2019-05-30 |
2022-08-04 |
ブリストル-マイヤーズ スクイブ カンパニー |
多腫瘍遺伝子シグネチャーおよびその使用
|
SG11202113154YA
(en)
|
2019-05-31 |
2021-12-30 |
Ikena Oncology Inc |
Tead inhibitors and uses thereof
|
CN114340735B
(zh)
|
2019-06-28 |
2024-11-12 |
璟尚生物制药公司 |
突变的TGFβ1-RII胞外域和免疫球蛋白支架组成的抗肿瘤拮抗剂
|
CA3147276A1
(en)
|
2019-08-02 |
2021-02-11 |
Amgen Inc. |
Kif18a inhibitors
|
EP4007756A1
(en)
|
2019-08-02 |
2022-06-08 |
Amgen Inc. |
Kif18a inhibitors
|
WO2021026098A1
(en)
|
2019-08-02 |
2021-02-11 |
Amgen Inc. |
Kif18a inhibitors
|
CA3147272A1
(en)
|
2019-08-02 |
2021-02-11 |
Amgen Inc. |
Kif18a inhibitors
|
US20220306630A1
(en)
|
2019-08-06 |
2022-09-29 |
Bristol-Myers Squibb Company |
AGONISTS OF ROR GAMMAt
|
AR119821A1
(es)
|
2019-08-28 |
2022-01-12 |
Bristol Myers Squibb Co |
Compuestos de piridopirimidinonilo sustituidos útiles como activadores de células t
|
MX2022002877A
(es)
|
2019-09-13 |
2022-08-08 |
Nimbus Saturn Inc |
Antagonistas de cinasa progenitora hematopoyetica 1 (hpk1) y sus usos.
|
CN114502590A
(zh)
|
2019-09-18 |
2022-05-13 |
诺华股份有限公司 |
Entpd2抗体、组合疗法、以及使用这些抗体和组合疗法的方法
|
JP7650867B2
(ja)
|
2019-09-19 |
2025-03-25 |
ブリストル-マイヤーズ スクイブ カンパニー |
酸性pHでVISTAと結合する抗体
|
AU2020353055B2
(en)
|
2019-09-26 |
2024-03-07 |
Gilead Sciences, Inc. |
Antiviral pyrazolopyridinone compounds
|
TW202128191A
(zh)
|
2019-10-21 |
2021-08-01 |
瑞士商諾華公司 |
Tim-3抑制劑及其用途
|
CA3158298A1
(en)
|
2019-10-21 |
2021-04-29 |
Novartis Ag |
Combination therapies with venetoclax and tim-3 inhibitors
|
AU2020369569A1
(en)
|
2019-10-24 |
2022-04-14 |
Amgen Inc. |
Pyridopyrimidine derivatives useful as KRAS G12C and KRAS G12D inhibitors in the treatment of cancer
|
WO2021091967A1
(en)
|
2019-11-04 |
2021-05-14 |
Revolution Medicines, Inc. |
Ras inhibitors
|
BR112022008535A2
(pt)
|
2019-11-04 |
2022-08-09 |
Revolution Medicines Inc |
Composto, composição farmacêutica, métodos para tratar câncer e um distúrbio relativo à proteína ras
|
JP2022553858A
(ja)
|
2019-11-04 |
2022-12-26 |
レボリューション メディシンズ インコーポレイテッド |
Ras阻害剤
|
TW202128688A
(zh)
|
2019-11-08 |
2021-08-01 |
美商銳新醫藥公司 |
雙環雜芳基化合物及其用途
|
AU2020383535A1
(en)
|
2019-11-14 |
2022-05-05 |
Amgen Inc. |
Improved synthesis of KRAS G12C inhibitor compound
|
EP4058453A1
(en)
|
2019-11-14 |
2022-09-21 |
Amgen Inc. |
Improved synthesis of kras g12c inhibitor compound
|
CA3158976A1
(en)
|
2019-11-19 |
2021-05-27 |
Bristol-Myers Squibb Company |
Compounds useful as inhibitors of helios protein
|
EP4065226A1
(en)
|
2019-11-26 |
2022-10-05 |
Bristol-Myers Squibb Company |
Salts/cocrystals of (r)-n-(4-chlorophenyl)-2-((1s,4s)-4-(6-fluoroquinolin-4-yl)cyclohexyl)propanamide
|
WO2021108528A1
(en)
|
2019-11-26 |
2021-06-03 |
Ikena Oncology, Inc. |
Polymorphic carbazole derivatives and uses thereof
|
KR20220104217A
(ko)
|
2019-11-26 |
2022-07-26 |
노파르티스 아게 |
Cd19 및 cd22 키메라 항원 수용체 및 이의 용도
|
BR112022010206A2
(pt)
|
2019-11-26 |
2022-11-29 |
Novartis Ag |
Receptores de antígeno quiméricos e usos dos mesmos
|
EP4065231A1
(en)
|
2019-11-27 |
2022-10-05 |
Revolution Medicines, Inc. |
Covalent ras inhibitors and uses thereof
|
IL293350A
(en)
|
2019-11-27 |
2022-07-01 |
Myst Therapeutics Llc |
Method of producing tumor-reactive t cell composition using modulatory agents
|
GB201917254D0
(en)
|
2019-11-27 |
2020-01-08 |
Adc Therapeutics Sa |
Combination therapy
|
US20230114107A1
(en)
|
2019-12-17 |
2023-04-13 |
Flagship Pioneering Innovations V, Inc. |
Combination anti-cancer therapies with inducers of iron-dependent cellular disassembly
|
BR112022011651A2
(pt)
|
2019-12-17 |
2022-08-23 |
Kymera Therapeutics Inc |
Degradadores de irak e usos dos mesmos
|
EP4076524A4
(en)
|
2019-12-17 |
2023-11-29 |
Kymera Therapeutics, Inc. |
IRAQ DEGRADATION AGENTS AND THEIR USES
|
KR20220116257A
(ko)
|
2019-12-20 |
2022-08-22 |
노파르티스 아게 |
골수섬유증 및 골수이형성 증후군을 치료하기 위한, 데시타빈 또는 항 pd-1 항체 스파르탈리주맙을 포함하거나 또는 포함하지 않는, 항 tim-3 항체 mbg453 및 항 tgf-베타 항체 nis793의 조합물
|
WO2021133749A1
(en)
|
2019-12-23 |
2021-07-01 |
Bristol-Myers Squibb Company |
Substituted piperazine derivatives useful as t cell activators
|
JP2023509394A
(ja)
|
2019-12-23 |
2023-03-08 |
カイメラ セラピューティクス, インコーポレイテッド |
Smarca分解剤およびそれらの使用
|
CN114846015B
(zh)
|
2019-12-23 |
2024-07-30 |
百时美施贵宝公司 |
用作t细胞激活剂的经取代的杂芳基化合物
|
EP4081516B1
(en)
|
2019-12-23 |
2025-07-30 |
Bristol-Myers Squibb Company |
Substituted quinazolinyl compounds useful as t cell activators
|
AR120823A1
(es)
|
2019-12-23 |
2022-03-23 |
Bristol Myers Squibb Co |
Compuestos bicíclicos sustituidos útiles como activadores de células t
|
JP7653441B2
(ja)
|
2019-12-23 |
2025-03-28 |
ブリストル-マイヤーズ スクイブ カンパニー |
T細胞アクティベーターとして有用な置換キノリノニルピペラジン化合物
|
KR20230020379A
(ko)
|
2020-01-06 |
2023-02-10 |
하이파이바이오 (에이치케이) 리미티드 |
항-tnfr2 항체 및 이의 용도
|
JP7719799B2
(ja)
|
2020-01-07 |
2025-08-06 |
ハイファイバイオ, インコーポレイテッド |
抗ガレクチン-9抗体およびその使用
|
CN114929279A
(zh)
|
2020-01-07 |
2022-08-19 |
锐新医药公司 |
Shp2抑制剂给药和治疗癌症的方法
|
AU2021207348A1
(en)
|
2020-01-17 |
2022-08-11 |
Novartis Ag |
Combination comprising a TIM-3 inhibitor and a hypomethylating agent for use in treating myelodysplastic syndrome or chronic myelomonocytic leukemia
|
WO2021163618A1
(en)
|
2020-02-14 |
2021-08-19 |
Novartis Ag |
Method of predicting response to chimeric antigen receptor therapy
|
IL295934A
(en)
|
2020-02-27 |
2022-10-01 |
Myst Therapeutics Llc |
Methods for ex vivo enrichment and expansion of tumor reactive t cells and related compositions thereof
|
EP4110377A2
(en)
|
2020-02-27 |
2023-01-04 |
Novartis AG |
Methods of making chimeric antigen receptor-expressing cells
|
WO2021171264A1
(en)
|
2020-02-28 |
2021-09-02 |
Novartis Ag |
Dosing of a bispecific antibody that binds cd123 and cd3
|
CN115515685B
(zh)
|
2020-03-03 |
2025-04-08 |
皮克医疗公司 |
Eif4e抑制剂及其用途
|
CA3168173A1
(en)
|
2020-03-06 |
2021-09-10 |
Robert Babb |
Anti-gitr antibodies and uses thereof
|
KR20220151189A
(ko)
|
2020-03-09 |
2022-11-14 |
브리스톨-마이어스 스큅 컴퍼니 |
증진된 효능제 활성을 갖는 cd40에 대한 항체
|
AU2021240046A1
(en)
|
2020-03-19 |
2022-09-29 |
Kymera Therapeutics, Inc. |
MDM2 degraders and uses thereof
|
CN115298165B
(zh)
|
2020-03-19 |
2024-09-17 |
艾库斯生物科学有限公司 |
作为HIF-2α抑制剂的四氢化萘和四氢喹啉化合物
|
TW202140441A
(zh)
|
2020-03-23 |
2021-11-01 |
美商必治妥美雅史谷比公司 |
經取代之側氧基異吲哚啉化合物
|
US20230149462A1
(en)
|
2020-04-10 |
2023-05-18 |
Juno Therapeutics, Inc. |
Methods and uses related to cell therapy engineered with a chimeric antigen receptor targeting b-cell maturation antigen
|
US20230192867A1
(en)
|
2020-05-15 |
2023-06-22 |
Bristol-Myers Squibb Company |
Antibodies to garp
|
KR20230019152A
(ko)
|
2020-06-02 |
2023-02-07 |
아르커스 바이오사이언시즈 인코포레이티드 |
Tigit에 대한 항체
|
WO2021247897A1
(en)
|
2020-06-03 |
2021-12-09 |
Kymera Therapeutics, Inc. |
Deuterated irak degraders and uses thereof
|
TW202210483A
(zh)
|
2020-06-03 |
2022-03-16 |
美商凱麥拉醫療公司 |
Irak降解劑之結晶型
|
CN116096862A
(zh)
|
2020-06-11 |
2023-05-09 |
诺华股份有限公司 |
Zbtb32抑制剂及其用途
|
MX2022016355A
(es)
|
2020-06-18 |
2023-04-03 |
Revolution Medicines Inc |
Metodos para retardar, prevenir, y tratar la resistencia adquirida a inhibidores de ras.
|
WO2021258010A1
(en)
|
2020-06-19 |
2021-12-23 |
Gossamer Bio Services, Inc. |
Oxime compounds useful as t cell activators
|
MX2022015852A
(es)
|
2020-06-23 |
2023-01-24 |
Novartis Ag |
Regimen de dosificacion que comprende derivados de 3-(1-oxoisoindolin-2-il)piperidina-2,6-diona.
|
CN116096906A
(zh)
|
2020-06-29 |
2023-05-09 |
旗舰创业创新五公司 |
工程化以促进萨诺传递的病毒及其在治疗癌症中的用途
|
MX2023001217A
(es)
|
2020-07-30 |
2023-03-03 |
Kymera Therapeutics Inc |
Metodos de tratamiento de linfomas mutantes.
|
EP4188549A1
(en)
|
2020-08-03 |
2023-06-07 |
Novartis AG |
Heteroaryl substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
|
MX2023001707A
(es)
|
2020-08-10 |
2023-05-04 |
Shanghai Xunbaihui Biotechnology Co Ltd |
Composiciones y métodos para el tratamiento de enfermedades autoinmunes y cánceres por direccionamiento al miembro 8 de la superfamilia de inmunoglobulinas.
|
US20240240255A1
(en)
|
2020-08-17 |
2024-07-18 |
Bicycletx Limited |
Bicycle conjugates specific for nectin-4 and uses thereof
|
US20230338587A1
(en)
|
2020-08-31 |
2023-10-26 |
Advanced Accelerator Applications International Sa |
Method of treating psma-expressing cancers
|
EP4204021A1
(en)
|
2020-08-31 |
2023-07-05 |
Advanced Accelerator Applications International S.A. |
Method of treating psma-expressing cancers
|
EP4204453A1
(en)
|
2020-08-31 |
2023-07-05 |
Bristol-Myers Squibb Company |
Cell localization signature and immunotherapy
|
AU2021344830A1
(en)
|
2020-09-03 |
2023-04-06 |
Revolution Medicines, Inc. |
Use of SOS1 inhibitors to treat malignancies with SHP2 mutations
|
CN117683049A
(zh)
|
2020-09-15 |
2024-03-12 |
锐新医药公司 |
作为ras抑制剂以治疗癌症的吲哚衍生物
|
US20230374064A1
(en)
|
2020-10-05 |
2023-11-23 |
Bristol-Myers Squibb Company |
Methods for concentrating proteins
|
CA3198447A1
(en)
|
2020-11-13 |
2022-05-19 |
Novartis Ag |
Combination therapies with chimeric antigen receptor (car)-expressing cells
|
US20240238271A1
(en)
|
2020-11-25 |
2024-07-18 |
Shanghai Juncell Therapeutics Co., Ltd. |
Pharmaceutical composition for enhancing cell killing, and use thereof
|
EP4253530A4
(en)
|
2020-11-25 |
2024-10-30 |
Shanghai Juncell Therapeutics Co., Ltd. |
TUMOR INFILTRATION LYMPHOCYTE CULTURE MEDIUM AND ITS APPLICATION
|
WO2022120353A1
(en)
|
2020-12-02 |
2022-06-09 |
Ikena Oncology, Inc. |
Tead inhibitors and uses thereof
|
EP4255895A1
(en)
|
2020-12-02 |
2023-10-11 |
Ikena Oncology, Inc. |
Tead inhibitors and uses thereof
|
WO2022120179A1
(en)
|
2020-12-03 |
2022-06-09 |
Bristol-Myers Squibb Company |
Multi-tumor gene signatures and uses thereof
|
CA3204091A1
(en)
|
2020-12-08 |
2022-06-16 |
Infinity Pharmaceuticals, Inc. |
Eganelisib for use in the treatment of pd-l1 negative cancer
|
EP4267250A1
(en)
|
2020-12-22 |
2023-11-01 |
Qilu Regor Therapeutics Inc. |
Sos1 inhibitors and uses thereof
|
EP4566674A3
(en)
|
2020-12-28 |
2025-08-06 |
Bristol-Myers Squibb Company |
Antibody compositions and methods of use thereof
|
WO2022146948A1
(en)
|
2020-12-28 |
2022-07-07 |
Bristol-Myers Squibb Company |
Subcutaneous administration of pd1/pd-l1 antibodies
|
IL303987A
(en)
|
2020-12-30 |
2023-08-01 |
Kymera Therapeutics Inc |
IRAK joints and their uses
|
CN116761622A
(zh)
*
|
2021-01-08 |
2023-09-15 |
苏州丁孚靶点生物技术有限公司 |
药物产品及其用途
|
US20250186539A2
(en)
|
2021-01-11 |
2025-06-12 |
Bicycletx Limited |
Methods for treating cancer
|
EP4288430A1
(en)
|
2021-02-02 |
2023-12-13 |
Liminal Biosciences Limited |
Gpr84 antagonists and uses thereof
|
BR112023015590A2
(pt)
|
2021-02-02 |
2023-10-17 |
Liminal Biosciences Ltd |
Antagonistas de gpr84 e usos dos mesmos
|
TW202246334A
(zh)
|
2021-02-02 |
2022-12-01 |
美商美國禮來大藥廠 |
Gitr拮抗劑及其使用方法
|
WO2022169921A1
(en)
|
2021-02-04 |
2022-08-11 |
Bristol-Myers Squibb Company |
Benzofuran compounds as sting agonists
|
WO2022174253A1
(en)
|
2021-02-12 |
2022-08-18 |
Nimbus Saturn, Inc. |
Hpk1 antagonists and uses thereof
|
US20240368150A1
(en)
|
2021-02-12 |
2024-11-07 |
Hoffmann-La Roche Inc. |
Bicyclic tetrahydroazepine derivatives for the treatment of cancer
|
IL304905A
(en)
|
2021-02-15 |
2023-10-01 |
Kymera Therapeutics Inc |
IRAK4 joints and their uses
|
AU2022220043A1
(en)
|
2021-02-15 |
2023-08-31 |
Kymera Therapeutics, Inc. |
Irak4 degraders and uses thereof
|
GB202102396D0
(en)
|
2021-02-19 |
2021-04-07 |
Adc Therapeutics Sa |
Molecular adjuvant
|
US11926625B2
(en)
|
2021-03-05 |
2024-03-12 |
Nimbus Saturn, Inc. |
HPK1 antagonists and uses thereof
|
US20240199648A1
(en)
|
2021-03-08 |
2024-06-20 |
Blueprint Medicines Corporation |
Map4k1 inhibitors
|
US11918582B2
(en)
|
2021-03-15 |
2024-03-05 |
Rapt Therapeutics, Inc. |
Pyrazole pyrimidine compounds and uses thereof
|
JP2024513011A
(ja)
|
2021-03-29 |
2024-03-21 |
ニンバス サターン, インコーポレイテッド |
Hpk1アンタゴニスト及びその使用
|
WO2022212784A1
(en)
|
2021-03-31 |
2022-10-06 |
Flagship Pioneering Innovations V, Inc. |
Thanotransmission polypeptides and their use in treating cancer
|
WO2022212876A1
(en)
|
2021-04-02 |
2022-10-06 |
The Regents Of The University Of California |
Antibodies against cleaved cdcp1 and uses thereof
|
KR20230167067A
(ko)
|
2021-04-05 |
2023-12-07 |
브리스톨-마이어스 스큅 컴퍼니 |
암의 치료를 위한 피리디닐 치환된 옥소이소인돌린 화합물
|
RS66982B1
(sr)
|
2021-04-06 |
2025-07-31 |
Bristol Myers Squibb Co |
Piridinil supstituisana oksoizoindolinska jedinjenja
|
TW202304979A
(zh)
|
2021-04-07 |
2023-02-01 |
瑞士商諾華公司 |
抗TGFβ抗體及其他治療劑用於治療增殖性疾病之用途
|
CA3214952A1
(en)
|
2021-04-09 |
2022-10-13 |
Silvana Marcel LEIT DE MORADEI |
Cbl-b modulators and uses thereof
|
WO2022221866A1
(en)
|
2021-04-16 |
2022-10-20 |
Ikena Oncology, Inc. |
Mek inhibitors and uses thereof
|
EP4334324A1
(en)
|
2021-05-05 |
2024-03-13 |
Revolution Medicines, Inc. |
Covalent ras inhibitors and uses thereof
|
AU2022270116A1
(en)
|
2021-05-05 |
2023-12-21 |
Revolution Medicines, Inc. |
Ras inhibitors
|
IL308195A
(en)
|
2021-05-05 |
2024-01-01 |
Revolution Medicines Inc |
RAS inhibitors for cancer treatment
|
PH12023500023A1
(en)
|
2021-05-07 |
2024-03-11 |
Kymera Therapeutics Inc |
Cdk2 degraders and uses thereof
|
KR102475255B1
(ko)
*
|
2021-05-10 |
2022-12-09 |
메디맵바이오 주식회사 |
항-gitr 항체 및 이의 용도
|
AR125874A1
(es)
|
2021-05-18 |
2023-08-23 |
Novartis Ag |
Terapias de combinación
|
EP4341261A1
(en)
|
2021-05-21 |
2024-03-27 |
Arcus Biosciences, Inc. |
Axl compounds
|
EP4341262A1
(en)
|
2021-05-21 |
2024-03-27 |
Arcus Biosciences, Inc. |
Axl inhibitor compounds
|
TW202307210A
(zh)
|
2021-06-01 |
2023-02-16 |
瑞士商諾華公司 |
Cd19和cd22嵌合抗原受體及其用途
|
KR20240049794A
(ko)
|
2021-06-07 |
2024-04-17 |
프로비던스 헬스 앤드 서비시즈 - 오레곤 |
Cxcr5, pd-1, 및 icos 발현 종양 반응성 cd4 t 세포 및 그의 용도
|
WO2023278641A1
(en)
|
2021-06-29 |
2023-01-05 |
Flagship Pioneering Innovations V, Inc. |
Immune cells engineered to promote thanotransmission and uses thereof
|
MX2024000751A
(es)
|
2021-07-14 |
2024-03-25 |
Blueprint Medicines Corp |
Compuestos heterociclicos como inhibidores de map4k1.
|
WO2023028235A1
(en)
|
2021-08-25 |
2023-03-02 |
PIC Therapeutics, Inc. |
Eif4e inhibitors and uses thereof
|
CN118019739A
(zh)
|
2021-08-25 |
2024-05-10 |
皮克医疗公司 |
Eif4e抑制剂及其用途
|
JP2024532931A
(ja)
|
2021-09-08 |
2024-09-10 |
レドナ・セラピューティクス,インコーポレーテッド |
Papd5及び/またはpapd7を阻害する4-オキソ-1,4-ジヒドロキノリン-3-カルボン酸誘導体
|
AR127308A1
(es)
|
2021-10-08 |
2024-01-10 |
Revolution Medicines Inc |
Inhibidores ras
|
US12071411B2
(en)
|
2021-10-29 |
2024-08-27 |
Arcus Biosciences, Inc. |
Inhibitors of HIF-2α and methods of use thereof
|
WO2023076556A1
(en)
|
2021-10-29 |
2023-05-04 |
Kymera Therapeutics, Inc. |
Irak4 degraders and synthesis thereof
|
WO2023114984A1
(en)
|
2021-12-17 |
2023-06-22 |
Ikena Oncology, Inc. |
Tead inhibitors and uses thereof
|
EP4448526A1
(en)
|
2021-12-17 |
2024-10-23 |
Genzyme Corporation |
Pyrazolopyrazine compounds as shp2 inhibitors
|
WO2023122778A1
(en)
|
2021-12-22 |
2023-06-29 |
Gossamer Bio Services, Inc. |
Pyridazinone derivatives useful as t cell activators
|
WO2023122777A1
(en)
|
2021-12-22 |
2023-06-29 |
Gossamer Bio Services, Inc. |
Oxime derivatives useful as t cell activators
|
WO2023122772A1
(en)
|
2021-12-22 |
2023-06-29 |
Gossamer Bio Services, Inc. |
Oxime derivatives useful as t cell activators
|
AU2023214044A1
(en)
|
2022-01-31 |
2024-08-08 |
Kymera Therapeutics, Inc. |
Irak degraders and uses thereof
|
JP2025503312A
(ja)
|
2022-02-01 |
2025-01-30 |
アルビナス・オペレーションズ・インコーポレイテッド |
Dgk標的化化合物およびその使用
|
EP4227307A1
(en)
|
2022-02-11 |
2023-08-16 |
Genzyme Corporation |
Pyrazolopyrazine compounds as shp2 inhibitors
|
EP4479388A1
(en)
|
2022-02-14 |
2024-12-25 |
Gilead Sciences, Inc. |
Antiviral naphthyridinone compounds
|
CN119136806A
(zh)
|
2022-03-08 |
2024-12-13 |
锐新医药公司 |
用于治疗免疫难治性肺癌的方法
|
EP4490166A1
(en)
|
2022-03-09 |
2025-01-15 |
Bristol-Myers Squibb Company |
Transient expression of therapeutic proteins
|
WO2023173053A1
(en)
|
2022-03-10 |
2023-09-14 |
Ikena Oncology, Inc. |
Mek inhibitors and uses thereof
|
WO2023173057A1
(en)
|
2022-03-10 |
2023-09-14 |
Ikena Oncology, Inc. |
Mek inhibitors and uses thereof
|
WO2023175614A1
(en)
|
2022-03-15 |
2023-09-21 |
Yeda Research And Development Co. Ltd. |
Anti glucocorticoid-induced tnfr-related (gitr) protein antibodies and uses thereof
|
MX2024011278A
(es)
|
2022-03-15 |
2024-09-25 |
Compugen Ltd |
Anticuerpos antagonistas de il-18bp y su uso en monoterapia y terapia de combinacion en el tratamiento del cancer.
|
KR20240159621A
(ko)
|
2022-03-18 |
2024-11-05 |
브리스톨-마이어스 스큅 컴퍼니 |
폴리펩티드를 단리하는 방법
|
WO2023211889A1
(en)
|
2022-04-25 |
2023-11-02 |
Ikena Oncology, Inc. |
Polymorphic compounds and uses thereof
|
KR20250006959A
(ko)
|
2022-05-02 |
2025-01-13 |
아르커스 바이오사이언시즈 인코포레이티드 |
항-tigit 항체 및 이의 용도
|
WO2023215560A1
(en)
|
2022-05-05 |
2023-11-09 |
Atoosa Corporation |
Tumor cell/immune cell multivalent receptor engager – bio-nanoparticle (timre-bnp)
|
KR20250040894A
(ko)
|
2022-05-25 |
2025-03-25 |
이케나 온콜로지, 인코포레이티드 |
Mek 억제제 및 이의 용도
|
KR20250022071A
(ko)
|
2022-06-02 |
2025-02-14 |
브리스톨-마이어스 스큅 컴퍼니 |
항체 조성물 및 이의 이용 방법
|
EP4536364A1
(en)
|
2022-06-10 |
2025-04-16 |
Revolution Medicines, Inc. |
Macrocyclic ras inhibitors
|
EP4543923A1
(en)
|
2022-06-22 |
2025-04-30 |
Juno Therapeutics, Inc. |
Treatment methods for second line therapy of cd19-targeted car t cells
|
US20240124490A1
(en)
|
2022-07-15 |
2024-04-18 |
Arcus Biosciences, Inc. |
Inhibitors of hpk1 and methods of use thereof
|
EP4558501A1
(en)
|
2022-07-20 |
2025-05-28 |
Arcus Biosciences, Inc. |
Cbl-b inhibitors and methods of use thereof
|
IL318575A
(en)
|
2022-08-02 |
2025-03-01 |
Liminal Biosciences Ltd |
HETEROARYL CARBOXAMIDE AND GPR84-RELATED ANTAGONISTS AND USES THEREOF
|
EP4565564A1
(en)
|
2022-08-02 |
2025-06-11 |
Liminal Biosciences Limited |
Substituted pyridone gpr84 antagonists and uses thereof
|
EP4565569A1
(en)
|
2022-08-02 |
2025-06-11 |
Liminal Biosciences Limited |
Aryl-triazolyl and related gpr84 antagonists and uses thereof
|
US20240041929A1
(en)
|
2022-08-05 |
2024-02-08 |
Juno Therapeutics, Inc. |
Chimeric antigen receptors specific for gprc5d and bcma
|
CN119654312A
(zh)
|
2022-08-08 |
2025-03-18 |
百时美施贵宝公司 |
用作t细胞活化剂的取代的四唑基化合物
|
WO2024036101A1
(en)
|
2022-08-09 |
2024-02-15 |
Bristol-Myers Squibb Company |
Tertiary amine substituted bicyclic compounds useful as t cell activators
|
EP4568960A1
(en)
|
2022-08-11 |
2025-06-18 |
F. Hoffmann-La Roche AG |
Bicyclic tetrahydroazepine derivatives
|
AU2023322638A1
(en)
|
2022-08-11 |
2024-11-28 |
F. Hoffmann-La Roche Ag |
Bicyclic tetrahydrothiazepine derivatives
|
JP2025526683A
(ja)
|
2022-08-11 |
2025-08-15 |
エフ・ホフマン-ラ・ロシュ・アクチェンゲゼルシャフト |
二環式テトラヒドロチアゼピン誘導体
|
AU2023322637A1
(en)
|
2022-08-11 |
2024-11-14 |
F. Hoffmann-La Roche Ag |
Bicyclic tetrahydrothiazepine derivatives
|
TW202421150A
(zh)
|
2022-09-14 |
2024-06-01 |
美商阿克思生物科學有限公司 |
艾魯美冷之分散體
|
WO2024077191A1
(en)
|
2022-10-05 |
2024-04-11 |
Flagship Pioneering Innovations V, Inc. |
Nucleic acid molecules encoding trif and additionalpolypeptides and their use in treating cancer
|
EP4602041A1
(en)
|
2022-10-14 |
2025-08-20 |
Arcus Biosciences, Inc. |
Hpk1 inhibitors and methods of use thereof
|
PE20251879A1
(es)
|
2022-10-14 |
2025-07-22 |
Black Diamond Therapeutics Inc |
Metodos de tratamiento del cancer usando derivados de isoquinolina o 6-aza-quinolina
|
TW202428286A
(zh)
|
2022-10-20 |
2024-07-16 |
美商阿克思生物科學有限公司 |
Cd73化合物之凍乾配方
|
AR131141A1
(es)
|
2022-11-22 |
2025-02-19 |
Pic Therapeutics Inc |
Inhibidores de eif4e y usos de los mismos
|
AR131320A1
(es)
|
2022-12-13 |
2025-03-05 |
Juno Therapeutics Inc |
Receptores de antígenos quiméricos específicos para baff-r y cd19 y métodos y usos de los mismos
|
WO2024137865A1
(en)
|
2022-12-22 |
2024-06-27 |
Gossamer Bio Services, Inc. |
Compounds useful as t cell activators
|
US20240269251A1
(en)
|
2023-01-09 |
2024-08-15 |
Flagship Pioneering Innovations V, Inc. |
Genetic switches and their use in treating cancer
|
TW202504611A
(zh)
|
2023-03-30 |
2025-02-01 |
美商銳新醫藥公司 |
用於誘導ras gtp水解之組合物及其用途
|
WO2024211712A1
(en)
|
2023-04-07 |
2024-10-10 |
Revolution Medicines, Inc. |
Condensed macrocyclic compounds as ras inhibitors
|
AR132338A1
(es)
|
2023-04-07 |
2025-06-18 |
Revolution Medicines Inc |
Inhibidores de ras
|
US20240352038A1
(en)
|
2023-04-14 |
2024-10-24 |
Revolution Medicines, Inc. |
Crystalline forms of ras inhibitors, compositions containing the same, and methods of use thereof
|
TW202446388A
(zh)
|
2023-04-14 |
2024-12-01 |
美商銳新醫藥公司 |
Ras抑制劑之結晶形式、含有其之組合物及其使用方法
|
TW202508595A
(zh)
|
2023-05-04 |
2025-03-01 |
美商銳新醫藥公司 |
用於ras相關疾病或病症之組合療法
|
US20240425497A1
(en)
|
2023-05-05 |
2024-12-26 |
Arcus Biosciences, Inc. |
Cbl-b Inhibitors and Methods of Use Thereof
|
WO2024233514A1
(en)
|
2023-05-08 |
2024-11-14 |
Bristol-Myers Squibb Company |
Substituted phenyl oxazolone compounds
|
WO2024243502A1
(en)
|
2023-05-25 |
2024-11-28 |
Arcus Biosciences, Inc. |
Cbl-b inhibitors and methods of use thereof
|
WO2024254227A1
(en)
|
2023-06-07 |
2024-12-12 |
Bristol-Myers Squibb Company |
Spirocyclic substituted oxoisoindolinyl piperidine-2,6-dione compound
|
WO2024263853A1
(en)
|
2023-06-23 |
2024-12-26 |
Bristol-Myers Squibb Company |
Substituted oxoisoindolinyl piperidine-2,6-dione compound as anticancer agent
|
TW202515608A
(zh)
|
2023-06-26 |
2025-04-16 |
以色列商坎布根有限公司 |
Il—18bp拮抗抗體及其於癌症治療之單一療法及組合療法的用途
|
WO2025030002A2
(en)
|
2023-08-02 |
2025-02-06 |
Arvinas Operations, Inc. |
Dgk targeting compounds and uses thereof
|
US20250049810A1
(en)
|
2023-08-07 |
2025-02-13 |
Revolution Medicines, Inc. |
Methods of treating a ras protein-related disease or disorder
|
WO2025038763A1
(en)
|
2023-08-15 |
2025-02-20 |
Bristol-Myers Squibb Company |
Ceramic hydroxyapatite chromatography flow through method
|
KR102834908B1
(ko)
|
2023-09-02 |
2025-07-16 |
브리스톨-마이어스 스큅 컴퍼니 |
치환된 페닐 옥소옥사졸릴 피페리딘 디온 화합물
|
WO2025064197A1
(en)
|
2023-09-02 |
2025-03-27 |
Bristol-Myers Squibb Company |
Substituted azetidinyl oxoisoindolinyl piperidine-2,6-dione compounds
|
WO2025054339A1
(en)
|
2023-09-08 |
2025-03-13 |
Arcus Biosciences, Inc. |
Triazolopyridine compounds as inhibitors of kit
|
WO2025059245A1
(en)
|
2023-09-13 |
2025-03-20 |
Bristol-Myers Squibb Company |
Substituted oxoisoindolinyl piperidine-2,6-dione compounds
|
WO2025072330A1
(en)
|
2023-09-26 |
2025-04-03 |
Arcus Biosciences, Inc. |
Kit inhibitor compounds and methods of use thereof
|
WO2025076299A1
(en)
|
2023-10-06 |
2025-04-10 |
Arcus Biosciences, Inc. |
Cbl-b inhibitors and methods of use thereof
|
US20250154171A1
(en)
|
2023-10-12 |
2025-05-15 |
Revolution Medicines, Inc. |
Ras inhibitors
|
WO2025096494A1
(en)
|
2023-10-31 |
2025-05-08 |
Bristol-Myers Squibb Company |
Ubiquitin specific processing protease 1 (usp1) compounds
|
WO2025096490A1
(en)
|
2023-10-31 |
2025-05-08 |
Bristol-Myers Squibb Company |
Ubiquitin specific processing protease 1 (usp1) compounds
|
WO2025096489A1
(en)
|
2023-10-31 |
2025-05-08 |
Bristol-Myers Squibb Company |
Ubiquitin specific processing protease 1 (usp1) compounds
|
WO2025096487A1
(en)
|
2023-10-31 |
2025-05-08 |
Bristol-Myers Squibb Company |
Ubiquitin specific processing protease 1 (usp1) compounds
|
US20250145590A1
(en)
|
2023-10-31 |
2025-05-08 |
Bristol-Myers Squibb Company |
Ubiquitin specific processing protease 1 (usp1) compounds
|
WO2025096505A1
(en)
|
2023-10-31 |
2025-05-08 |
Bristol-Myers Squibb Company |
Ubiquitin specific processing protease 1 (usp1) compounds
|
WO2025096488A1
(en)
|
2023-10-31 |
2025-05-08 |
Bristol-Myers Squibb Company |
Ubiquitin specific processing protease 1 (usp1) compounds
|
US12384773B2
(en)
|
2023-11-02 |
2025-08-12 |
Arcus Biosciences, Inc. |
Thiazole compounds and methods of use thereof
|
US20250230173A1
(en)
|
2023-12-20 |
2025-07-17 |
Arcus Biosciences, Inc. |
Salt forms of an axl inhibitor
|
WO2025137507A1
(en)
|
2023-12-22 |
2025-06-26 |
Regor Pharmaceuticals, Inc. |
Sos1 inhibitors and uses thereof
|
WO2025145207A1
(en)
|
2023-12-29 |
2025-07-03 |
Bristol-Myers Squibb Company |
Combination therapy of kras inhibitor and treg-depleting agent
|